Topic: cardiovascular outcomes
With some new Plavix-matching data, AstraZeneca may have just found a new niche for its blood thinner Brilinta.
Amgen has its sought-after approval to tout its PCSK9 cholesterol med Repatha as a cardiovascular prevention tool.
Sanofi, Regeneron and Amgen, locked in a PCSK9 market battle, are touting the cholesterol drugs' benefits for patients with diabetes.
Anyone looking for a heart-helping class effect from GLP-1 diabetes meds wouldn't be encouraged by the Bydureon data AstraZeneca rolled out Thursday.
In 2015, BI and Eli Lilly were the first to show that a diabetes med could cut the risk of CV death, and they’re still working to capitalize on that.
Novo’s combination med Xultophy, key to its growth strategy, can dampen CV risk factors such as LDL cholesterol, a new analysis showed.
AstraZeneca has pegged big hopes on its clot-fighter Brilinta, and it's rolling out numbers designed to advance them. Will it work?
With real-world cardiovascular outcomes, Amgen says Repatha is cost-effective at $9,669 per year.
Novo Nordisk, fighting competition to its blockbuster Victoza, just posted data on a follow-up drug that gives it an edge over archrival Trulicity.